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Purpose: This study aimed to describe seizures and their therapy among Swedish adolescents, aged 13–22, with active but
uncomplicated epilepsy.
Method: The adolescents answered questionnaires (158/193). Data were also obtained from medical records.
Results: Epileptic seizure types could be specified in 92.1% of the cases. Predominant types were Primary Generalised
Tonic–Clonic Seizures and Partial Complex Seizures with Secondary Generalisation. Clinical diagnoses by physicians were
unspecified in 25.8%. Ninety percent were on antiepileptic drugs (AEDs), most commonly valproate and carbamazepine. New
AEDs were used in 9.3% of the cases and polytherapy in 13.9%. More than 40% of the respondents had seizures despite AED
treatment. Side effects of AEDs were experienced by 61%, most commonly tiredness, concentration difficulties and headache.
Patients on polytherapy experienced significantly more side effects. The choice of a new AED over a traditional one was not
related to seizure type or seizure control.
Conclusions: Many adolescents had persistent seizures despite treatment at a specialist regional epilepsy centre. This, plus the
high reported rate of side effects of AED treatment, suggests that treatment is not optimal for the group studied. As traditional
AEDs strongly dominated treatment possibly newly marketed AEDs are underused in this group.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
In the epilepsy literature there are few studies focus-
ing on adolescents, although this period often means
changes in the epilepsy condition, difficulties in con-
trolling the epilepsy and poor compliance1, 2. Studies
have shown that epilepsy acquired in childhood can
continue to have a negative impact on the life situa-
tion in adulthood, although the epilepsy is well con-
trolled or in remission3, 4. The risk of social isolation,
which is a known epilepsy-related problem5–7 is, in
a general population, high in adolescence and young
adulthood8, 9 which can mean special problems for
young people with epilepsy. Seizure control can thus
be especially important for adolescents with epilepsy,
but difficult to achieve.
As a part of a larger study on quality of life in
adolescents with uncomplicated epilepsy, this study
concerns the seizures and therapy in this group. The
aim of this study was to describe seizures and therapy
among adolescents13–22, with active but uncompli-
cated epilepsy living in an area in the middle Sweden.
This part of the study was directed to see if adoles-
cents have a more difficult-to-control epilepsy and
more side effects of treatment, compared to studies
in children10, 11 and adults12.
METHOD
Definitions
In this study uncomplicated epilepsy was defined as
epilepsy with no initially associated neurological im-
pairment (mental retardation or cerebral palsy). The
diagnosis of epilepsy was defined as having had at
least two unprovoked epileptic seizures. Two types of
classification were used: (1) Classification of epileptic
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syndromes. Clinical diagnoses, according to WHO In-
ternational Classification of Diseases (ICD 10)13 made
by the patients’ physicians, were collected from the
medical records. (2) Classification of epileptic seizures
was made according to the International Classifica-
tions of the International League Against Epilepsy
(ILAE)14, 15 by one of the authors (BS). To classify
how well the epilepsy was controlled, we used the
same classification as Eriksson and Koivikko11.
(a) Good control: no seizures during the last year.
(b) Partial control: one or more seizures during the
last year, but not more than one per month.
(c) Poor control: more than one seizure per month.
Adolescence was defined as youth from 10 to 25
years of age16. This definition recognises the highly
individual span of the adolescent period. Young peo-
ple aged 18–22 in this study were still registered at
the paediatric department, the majority (76%) was at-
tending school and many (46%) still lived with their
parents.
The classification of age groups was made from a
development psychological perspective8, 9, 17.
Health-care system and study area
The Swedish National Board of Health and Wel-
fare in Sweden recommends that children and ado-
lescents with epilepsy should be managed by a
neuro-paediatrician or neurologist at specialised neu-
rology/child neurology centres (i.e. in major hospitals
with neurological and paediatric departments) and
not by general practitioners, or at minor hospitals or
other centres. This is accepted practice. Thus, this
study could be seen upon as a population-based study
concerning the areas studied. The study was carried
out in the regional areas of four major hospitals in
middle Sweden; the Linköping University Hospital,
the Örebro Regional Hospital and the County Hospi-
tals of Jönköping and Karlstad. The total population
of the four studied areas was approximately 125 000
in the age group 13–22.
Subjects
All adolescents, aged 13 through 22, registered with
an epilepsy diagnosis in the paediatric or neurological
department of four Swedish hospitals, were invited to
participate. Of 193 patients fulfilling the criteria, 158
(82%) (see the following description) returned mailed
questionnaires. Of those seven were removed from the
study at re-evaluation as it was discovered that they
suffered from ‘benign childhood epilepsy’. This left
151 participants, 84 girls and 67 boys. One boy had
had epilepsy surgery 1 year prior to this study, oth-
erwise AEDs were the only epilepsy treatment occur-
ring in the studied group. Of the 35 drop-outs 26 gave
no reason for not participating and five adolescents
‘felt that they had other things to do’. In four cases the
parents did not want their child to participate. There
were no significant differences between the drop-outs
and the patients who participated concerning of age,
sex, diagnosis, treatment or living circumstances.
Inclusion/exclusion criteria
To be included the adolescent should either have had
at least one epileptic seizure during the previous year
and/or be on AED treatment due to epilepsy. The ado-
lescent also had to be familiar with the Swedish lan-
guage. Exclusion criteria were additional neurological
impairments (most common; mental retardation, cere-
bral palsy) or other diseases (most common; asthma,
diabetes, psychiatric conditions) or handicaps (most
common; major physical handicap, obesity) that were
considered to have a substantial impact on a person’s
quality of life. All patients with the diagnosis ‘be-
nign childhood epilepsy’ were excluded. Three pa-
tients were excluded as they had been living abroad
for 1 year or more.
Instruments
A modified version of the National Hospital Seizure
Severity Scale, NHS3 (Donoghue 1994, Swedish
translation Malmgren 1994), was mailed to the ado-
lescents. As this instrument usually is filled in by the
physician at the patients visit to the clinic, the whole
instrument was rephrased to suit written self-reports.
One question about secondary generalisation was
deleted. Another question about seizure types was re-
placed with one where patients were asked to describe
their seizures. Three questions were added concern-
ing seizure frequency, drug treatment and side effects
of AED.
Another questionnaire on sex, age, diagnosis, time
of diagnosis, current drug treatment and living circum-
stances was developed. It was used to fill in informa-
tion from the patients’ medical records.
Procedure
To classify epileptic seizure types after the ILAE clas-
sification, one of the authors (BS) evaluated all records
in detail, including EEG registrations. We were able
to specify the epileptic seizure types in 92.1% of the
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cases. Epilepsy diagnoses made by the patients’ physi-
cians, classified in the medical records according to
ICD 1013, were recorded. Of those diagnoses 25.7%
were unspecified. In the majority of the records we
found that there was too little information to identify
epileptic syndromes. Therefore, we did not attempt to
make such a classification.
Written and oral information were repeatedly given
to all medical staff concerned during 3 months before
the study started and than continuously throughout
the study. Patients registered with an epilepsy diagno-
sis ‘99 02 28’ were identified by using the hospitals
diagnostic listing system. One nurse in each clinic
was asked to take out and write down the required in-
formation from the selected patients medical records.
A letter was sent out to all patients together with the
questionnaire. At the same time questionnaires on
quality of life were sent out (those results will be pub-
lished separately). In the letter they were informed
of the study and its aims, that it was voluntary and
that they were free to leave the study at any time.
The letter also contained telephone numbers for the
persons responsible for the study and to the doctor
and nurse to contact in their own clinic if they wanted
to make further enquiry. Added to the questionnaires
was a prepaid, addressed envelope and a note to send
in if the patient did not want to participate. Those
who participated gave their oral and/or written con-
sent. For those patients between the age of 13 and 17,
letters were addressed to parents, containing separate
information for parents and adolescents. Consent to
participate had to be given by both parents and the
adolescent. At two clinics the hospital staff contacted
the patients by telephone to first ask them if they
gave their consent to being contacted about a study
on epilepsy in adolescence.
Patients who had not returned the questionnaires or
the note to state that they did not want to partici-
pate by 14 days were reminded by telephone or by
mail.
Statistics
For statistical analyses the Statistical Package for
the Social Sciences Release 10.0 (SPSS 10.0)18, 19
was used. Frequencies were calculated and cross-
tabulations were carried out. Chi-square tests with
Yates continuity correction were used to test for
significance in nominal variables and Fisher’s exact
test if the total was 20 or less or if one or more ex-
pected frequencies were less than 5. Mann–Whitney’s
U-test and the Kruskal–Wallis test were used to test
for significance in ordinal variables. P-values <0.05
were considered as being significant20, 21. As pa-
tients with some seizure types were extremely few,
seizure classes were divided into five groups in most
analyses;
• Group 1: Absence Seizures (ABS), Myoclonic
Seizures (MCS) and Simple Partial Seizures With-
out Generalisation (SPS);a
• Group 2: Complex Partial Seizures Without Gen-
eralisation (CPS);
• Group 3: Simple and/or Complex Partial Seizures
with Secondary Generalisation (SPSG/CPSG);
• Group 4: Primary Generalised Tonic–Clonic
Seizures (TCS), TCS and ABS, TCS and MCS,
and TCS and CPS;
• Group 5: Unspecified Seizures (US).
Ethics
Those Swedish Ethics Committees concerned ap-
proved of the study.
RESULTS
By the time of the study 76% of the adolescents had
had their epilepsy diagnosis for more than 3 years.
Dominating seizure types were primary generalised
TCS and CPS with secondary generalisation. In 7.9%
of the cases the seizure type could not be specified
(Table 1). Traditional AEDs dominated as monother-
apy in all seizure types. New AEDs as monotherapy
were most common in CPS.
Gender did not relate significantly to different
seizure types but there was a tendency for girls to
have more seizures classified as group 1 (ABS and
MCS; Table 2). Patients with CPS had significantly
poorer epilepsy control than those with seizures clas-
sified as groups 4 and 5. No difference was seen in the
distribution of seizure types in different age groups
or between the number of years of having epilepsy in
patients with unspecified seizures compared to those
with specified. Nor did number of years of epilepsy
relate to the epilepsy diagnosis (specified or not). Dual
therapy was most commonly used in CPS (group 2)
and SPSG/CPSG (group 3). Medication-free patients
were not associated any with particular seizure type.
Ninety percent of the adolescents were on AED
treatment (Table 3) and of those 84.6% were on
monotherapy.
Most commonly used as monotherapy were val-
proate (VPA) and carbamazepine (CBZ). The majority
of patients suffering from primary generalised TCS
a Patients with SPS (n = 2) were (despite the partial nature of
the seizures) placed in group 1 as they have a mild condition that
was unlike to produce the problems of patients with CPS.
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Table 1: Classification of seizure types—n (%), distribution on gender, age groups, years of epilepsy, control of epilepsy and antiepileptic drugs (AEDs).
SPSa 2 CPSa 12 SPSGa 3 CPSGa 43 TCSa 32 ABSa 13 MCSa 13 CPS and ABS and TCSa MCS and TCSa USa 12 Total 151
(1.3) (7.9) (2) (28.5) (21.2) (8.6) (8.6) TCSa 1 (0.7) 18 (11.9) 2 (1.3) (7.9) (100)
Gender n (%)
Male 1 (1.5) 7 (10.4) 2 (3) 23 (34.3) 15 (22.4) 2 (3.0) 4 (6) 1 (1.5) 5 (7.5) 7 (10.5) 67 (100)
Female 1 (1.2) 5 (6) 1 (1.2) 20 (23.8) 17 (20.2) 11 (13.1) 9 (10.7) 13 (15.5) 2 (2.4) 5 (5.9) 84 (100)
Age n (%)
13–14 3 (15) 7 (35) 3 (15) 1 (5) 1 (5) 2 (10) 3 (15) 20 (100)
15–17 2 (6.9) 1 (3.4) 9 (31) 4 (13.8) 3 (10.3) 5 (17.2) 5 (17.2) 29 (100)
18–20 2 (3.6) 2 (3.6) 1 (1.8) 15 (27.3) 19 (34.5) 3 (5.5) 5 (9.1) 4 (7.3) 1 (1.8) 3 (5.5) 55 (100)
21–22 5 (10.6) 1 (2.1) 12 (25.5) 9 (19.1) 4 (8.5) 2 (4.3) 7 (14.9) 1 (2.1) 6 (12.8) 47 (100)
Years of epilepsy n (%)
<1 year 1 (33.3) 1 (33.3) 1 (33.3) 3 (100)
1–2 years 5 (15.2) 7 (21.2) 7 (21.2) 4 (12.1) 5 (15.2) 1 (3) 2 (6.1) 1 (3) 1 (3) 33 (100)
3–5 years 4 (8.3) 12 (25) 13 (27.1) 2 (4.2) 5 (10.4) 7 (14.6) 1 (2.1) 4 (8.3) 48 (100)
6–9 years 2 (5.7) 12 (34.3) 6 (17.1) 3 (8.6) 2 (5.7) 6 (17.1) 4 (11.4) 35 (100)
>10 years 2 (6.2) 3 (9.4) 1 (3.1) 12 (37.5) 5 (15.6) 3 (9.4) 1 (3.1) 2 (6.2) 3 (9.4) 32 (100)
Control of epilepsy n (%)
Good 2 (2.3) 7 (7.9) 1 (1.1) 19 (21.6) 20 (22.7) 7 (7.9) 8 (9.1) 12 (13.6) 2 (2.3) 10 (11.4) 88 (100)
Partial 1 (2.2) 2 (4.3) 18 (39.1) 10 (21.7) 5 (10.9) 3 (6.5) 1 (2.2) 4 (8.7) 2 (4.3) 46 (100)
Poor 4 (23.5) 6 (35.3) 2 (11.8) 1 (5.9) 2 (11.8) 2 (11.8) 17 (100)
AEDs n (%)
No drug 6 (40) 3 (20) 2 (13.3) 1 (6.7) 3 (20) 15 (100)
Traditional 1 (1) 6 (5.9) 2 (2) 22 (21.8) 25 (24.7) 9 (8.9) 13 (12.9) 1 (1) 14 (13.9) 1 (1) 7 (6.9) 101 (100)
New 3 (21.4) 1 (7.1) 3 (21.4) 4 (28.6) 2 (14.3) 1 (7.1) 14 (100)
Di-therapy 1 (4.8) 3 (14.3) 12 (57.1) 3 (14.3) 1 (4.8) 1 (4.8) 21 (100)
a Simple Partial Seizures (SPS), Complex Partial Seizures (CPS), Simple/Complex Partial Seizures with Secondary Generalisation (SPSG/CPSG), Primary Generalised Tonic–Clonic Seizures (TCS),
Absence Seizures (ABS), Myoclonic Seizures (MCS), Unspecified Seizures (US).
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Table 2: Differences in gender, age, years of epilepsy, control of epilepsy and use of antiepileptic drugs (AEDs) in relation to
seizure type.
SPS/MCS/ABS CPS SPSG/CPSG TCS/TCS+ US Statistics
Gender n (%)
Male 7 (10.4) 7 (10.4) 25 (37.3) 21 (31.3) 7 (10.4) χ2 = 8.49a, P = 0.07
Female 21 (25) 5 (6) 21 (25) 32 (38.1) 5 (6) χ2 = 8.49a, P = 0.07
Age M (SD) 17.86 (2.95) 18.17 (3.38) 18.24 (2.72) 19.00 (2.51) 19.08 (3.60) χ2 = 4.42b, P = 0.35
Years of epilepsy M (SD)c 3.21 (1.23) 3.08 (1.24) 3.72 (1.05) 3.21 (1.04) 3.75 (0.96) χ2 = 8.48b, P = 0.08
Control of epilepsy M (SD)d 2.50 (0.69) 2.25 (0.96) 2.30 (0.69) 2.57 (0.64)* 2.83 (0.39)** Z = 2.05e, P = 0.04;
Z = 2.48f, P = 0.01
AEDs n (%)
None 2 (7.1) 6 (13) 4 (7.5) 3 (25)
Monotherapy 25 (89.3) 9 (75) 28 (60.9) 45 (84.9) 8 (66.7)
Di-therapy 1 (3.6) 3 (25)*** 12 (26.1)*** 4 (7.5) 1 (8.3) χ2 = 12.10a, P = 0.001
Group 1: Simple Partial Seizures (SPS), Myoclonic Seizures (MCS), and Absence Seizures (ABS). Group 2: Complex Partial Seizures
(CPS). Group 3: Simple or Complex Partial Seizures with secondary generalisation (SPSG/CPSG). Group 4: Primary Generalised
Tonic–Clonic Seizures (TCS) and Tonic–Clonic Seizures in combination with MCS, TCS or CPS (TCS+). Group 5: Unspecified
Seizures (US).
a χ2 value from Chi-square test. Di-therapy was mostly used in groups 2 and 3; b χ2 value from Kruskal–Wallis test. Pair-wise tests
showed no differences; c Based on classification of years of epilepsy shown in Table 1; d Range from 1 to 3. High score reflects a
positive evaluation; e Differences between groups 2 and 4 in Z-transformed scores from the Mann–Whitney U-test; f Differences between
groups 2 and 5 in Z-transformed scores from the Mann–Whitney U-test.
* P < 0.05; ** P < 0.01; *** P < 0.001.
were on VPA and those with partial seizures with or
without generalisation on CBZ. New AEDs were used
as monotherapy in 9.3% of the cases and combinations
of two AEDs were present in 21 patients. Of those on
dual therapy one had Unspecified Seizures (Table 1)
and six an unspecified diagnosis (not shown in
table).
Table 3: Antiepileptic drugs (AEDs), n (%).
No AED drug Traditional AED 101 (66.9) New AEDs Combined therapy
15 (9.9) 14 (9.3)a 21 (13.9)bCarbamazepine Sodium valproate Ethosuximide Phenytoin
39 (25.8) 59 (39.1) 2 (1.3) 1 (0.7)
Gender n (%)
Male 10 (14.9) 20 (29.9) 20 (29.9) 8 (11.9) 9 (13.4)
Female 5 (6) 19 (22.6) 39 (46.4) 2 (2.4) 1 (1.2) 6 (7.1) 12 (14.3)
Age n (%)
13–14 4 (20) 5 (25) 5 (25) 4 (20) 2 (10)
15–17 5 (17.2) 8 (27.6) 10 (34.5) 2 (6.9) 1 (3.4) 3 (10.3)
18–20 1 (1.9) 15 (27.3) 27 (49.1) 5 (9.1) 7 (12.7)
21–22 5 (10.6) 11 (23.4) 17 (36.2) 1 (2.1) 4 (8.5) 9 (19.1)
Years of epilepsy n (%)
<1 year 1 (33.3) 1 (33.3) 1 (33.3)
1–2 years 1 (3) 11 (33.3) 16 (48.5) 1 (3) 4 (12.1)
3–5 years 5 (10.4) 11 (22.9) 23 (47.9) 1 (2.1) 5 (10.4) 3 (6.2)
6–9 years 4 (11.4) 7 (20) 14 (40) 4 (11.4) 6 (17.1)
10 years 4 (12.5) 9 (28.1) 5 (15.6) 1 (3.1) 1 (3.1) 4 (12.5) 8 (25)
Control of epilepsy n (%)
Good 8 (9) 22 (25) 39 (44.3) 1 (1.1) 1 (1.1) 7 (8) 10 (11.4)
Partial 6 (13.0) 14 (30.4) 15 (32.6) 1 (2.2) 6 (13.0) 4 (8.7)
Poor 1 (5.9) 3 (17.6) 5 (29.4) 1 (5.9) 7 (41.2)
a New AEDs as monotherapy: Lamotrigine (n = 10), Oxcarbamazepine (n = 2), Topiramate (n = 1), Gabapentin (n = 1); b Combination
of two traditional AEDs (n = 1), two new AEDs (n = 3), one traditional and one new AED (n = 17—Lamotrigine is used in 11
combinations, Topiramate in 4 and Vigabatrin in 2).
Patients on dual therapy had more years of epilepsy
and poorer control of epilepsy than those on monother-
apy with traditional AEDs (Table 4).
There was a tendency for using new AEDs more
frequently in patients with many years of epilepsy
(Mann–Whitney Z = 1.87, P = 0.06). There were no
differences in use of new AEDs in patients with un-
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Table 4: Differences in gender, age, years of epilepsy and control of epilepsy in relation to use of antiepileptic drugs (AEDs),
n (%).
No AED drug Traditional AED New AEDs Combined therapy Statistics
15 (9.9) 101 (66.9) 14 (9.2) 21 (13.9)
Gender n (%)
Male 10 (14.9) 40 (59.8) 8 (11.9) 9 (13.4) χ2 = 4.89a, P = 0.18
Female 5 (6) 61 (72.6) 6 (7.1) 12 (14.3) χ2 = 4.89a, P = 0.18
Age M (SD) 17.2 (3.23)* 18.66 (2.67) 18 (3.3) 18.95 (2.58) Fisher P = 0.02b
Years of epilepsy M (SD)c 3.6 (1.18) 3.22 (1.07) 3.79 (0.97) 3.86 (1.15)* Z = 2.33d, P = 0.02
Control of epilepsy M (SD) 2.47 (0.64) 2.54 (0.64) 2.43 (0.65) 2.14 (0.91)* Z = 1.98e, P = 0.05
a χ2 value from Chi-square test; b Differences between younger (13–17) and older patients (18–22) in Fisher’s exact test; c Based on
classification of years of epilepsy shown in Table 1; d Differences between patients on traditional monotherapy and di-therapy in
Z-transformed scores from Mann–Whitney U-test; e Differences between patients on traditional monotherapy and di-therapy in
Z-transformed scores from Mann–Whitney U-test.
* P < 0.05; **P < 0.01; ***P < 0.001.
controlled epilepsy compared to those who had had no
seizures during the last year. Medication-free patients
were more often seen among younger ages.
Side effects of AED were reported by 61% of the
adolescents and of those 20.5% reported three or more
side effects. Tiredness dominated but concentration
difficulties and headache were also rather common.
Patients treated with a combination of two AEDs ex-
perienced significantly more side effects as a whole.
No difference could be found concerning side effects
in connection with age or with traditional versus new
AEDs.
Almost 42% of the patients treated with AEDs re-
ported seizure activity during the last year and of those
11.3% were uncontrolled, e.g. patients had more than
one seizure a month. (Table 5).
Table 5: Control of epilepsy, n (%).
Good control 88 (58.3) Partial control 46 (30.5) Poor 17 (11.3) Total 151 (100)
Age n (%)
13–14 9 (45) 10 (50) 1 (5) 20 (100)
15–17 15 (51.7) 9 (31.0) 5 (17.2) 29 (100)
18–20 35 (63.6) 17 (30.9) 3 (5.5) 55 (100)
21–22 29 (61.7) 10 (21.3) 8 (17.0) 47 (100)
Monotherapy n (%) 70 (60.9) 36 (31.3) 9 (7.8) 115 (100)
Combined therapy 10 (47.6) 4 (19.0) 7 (33.3) 21 (100)
Years of epilepsy n (%)
<1 year 2 (66.6) 1 (33.3) 3 (100)
1–2 years 20 (60.6) 9 (27.3) 4 (12.1) 33 (100)
3–5 years 26 (54.2) 18 (37.5) 4 (8.3) 48 (100)
6–9 years 24 (68.6) 10 (28.6) 1 (2.9) 35 (100)
>10 years 16 (50) 8 (25) 8 (25) 32 (100)
Specified seizure n (%) 78 (56.1) 44 (31.6) 17 (12.2) 139 (100)
Unspecified seizure types 10 (83.3) 2 (16.7) 12 (100)
Specified diagnosis n (%) 65 (58) 35 (31.3) 17 (12.2) 112 (100)
Unspecified seizure types 23 (59) 11 (28.2) 5 (12.8) 39 (100)
Distribution on age groups, treatment with monotherapy/combined therapy, years of epilepsy, distribution on specified/unspecified
seizure types and specified/unspecified diagnoses.
Adolescents with an unspecified diagnosis showed
the same frequency of epileptic seizures as those with
a specified one. However, patients with unspecified
seizure types showed a tendency to better control
(not shown in table—Mann–Whitney Z = 1.91,
P = 0.06). Years of epilepsy had no connection with
how well controlled the epilepsy was. No relation was
found between seizure frequency and age or living
conditions.
Almost half of the patients had no time to put them-
selves into safety before seizures occurred. During
the seizure 58.4% experienced loss of consciousness.
The most common side effect of seizures was frequent
headache in 38.5% of the patients (severe headache in
16%). Slight injuries in connection with seizures oc-
curred often or always in 11.2%. Recovery time after
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seizures were more than 3 hours in almost 30% of the
cases.
Gender differences were not found in any of the
variables studied.
DISCUSSION
This study suggests that the treatment of adolescents
with epilepsy is less effective than in a similar Scan-
dinavian child population11 and for adult patients in
earlier studies12, 22. In the present study almost 42% of
the patients continued to have seizures despite contact
with specialised neurology/child neurology centres.
By limiting our study to four major hospital districts
where neurologists and neuro-paediatricians were at
hand, we believe that we have reached most adoles-
cents diagnosed with epilepsy within the area stud-
ied. Sidenvall23 did not find any patients registered
by general practitioners in a study on prevalence and
characteristics of epilepsy in Swedish children. Some
patients in the group we studied might still be regis-
tered elsewhere, especially as we studied uncompli-
cated epilepsy, and some of the patients were over the
age of 18. We consider high response rates and very
low internal drop-outs as strong points concerning
reliability.
NHS3 was chosen as a base instrument. It was inter-
nationally well known and clinically used in Sweden,
which increases the validity of the study. There were
difficulties in finding comparable studied groups con-
cerning the severity of epilepsy (uncomplicated) and
age (13–22). This must be taken into account when
comparing results from this study with others. NHS3
served well as a self-report tool in the group studied
but did not quite cover the area we wanted: a couple
of extra questions had to be added. One of those ques-
tions “Do you take drugs due to your epilepsy?” made
it possible to compare adolescent’s self-reports to the
medical records. Adolescents have been found to give
honest answers in questionnaires except for questions
concerning sex24. Concerning medication in the cur-
rent study the adolescents’ self-reported answers dif-
fered only in a few cases (n = 3) from what was
registered in their medical records. Where differences
were found the adolescents reported non-compliance,
i.e. that they refused to take prescribed medication.
One reason for better results in a child population is
that benign childhood epilepsy is included. At the age
of 13, most cases of benign childhood epilepsy have
spontaneously resolved. However, in those age groups
partly overlapping Eriksson and Koivikko’s11 (13–14
and 15–17 years old patients), 50% had suffered
from seizures during the last year compared to 24%
in Eriksson’s group (age 10–15). This discrepancy
cannot be fully explained by the different number of
patients with benign childhood epilepsy. Other stud-
ies of adult epilepsy patients25 have shown an even
lower proportion of seizure-free persons. Many fac-
tors make it difficult to directly compare the outcome
in different populations. Among these are selection
bias in the group studied and whether patients with
multi-handicap are included. As our study concerns
a group without other disorders the percentage of
seizure-free patients must be considered low.
It seems initially surprising that one fourth of the
patients originally had an unspecified diagnosis, the
majority after more than 3 years of treatment for
putative epilepsy. However, it is well known that the
diagnosis of epilepsy can be difficult: a further com-
plication is the lack of concordance between the ILAE
and the WHO ICD 10. This means that an unspecified
diagnosis in the medical record does thus not neces-
sarily mean that the neurologist or neuro-paediatrician
is not certain of the type of epilepsy and that infor-
mation about the epilepsy cannot be found in the
medical record.
Patients treated with a combination of two AEDs
more often had a poor epilepsy control compared
with those on monotherapy. Medication-free pa-
tients did not have significantly higher frequency of
seizures than patients on AEDs. These findings can
be explained by the fact that treatment reflects the
intractability of the epilepsy. Like Berg et al.26 in a
study in 1999, we found that traditional AEDs strongly
dominated treatment. New AEDs were primarily
used as add-on therapy, which is also in accordance
to recommendations of the Swedish Medical Prod-
ucts Agency, even if some new AEDs are approved
to be used as monotherapy in Sweden. Morton and
Pellock27 point out that the preference for traditional
AEDs over new ones is due to the wide experience
with traditional AEDs. Brodie and French28 have ad-
vocated that a wider use of a new AED can improve
the situation for many epilepsy patients. As our study
shows a low use of new AEDs, the therapeutic advan-
tages of some of these drugs were not fully utilised.
Other treatments like epilepsy surgery and vagal nerve
stimulation were not used. This does further increase
the impression of under-treatment in the study group.
There are studies25 that demonstrates that up to half
of epilepsy patients have side effects of AEDs. This
figure includes children and adolescents with severe
epilepsy and multi-handicap. We noted in our study
that adolescents with uncomplicated epilepsy had a
similar degree of side effects. Of our patients, 10%
were untreated. This is consistent with Berg’s group26
where patients with severe epilepsy and neurological
deficits were included.
More than 11% of the adolescents reported slight
injuries often or always in connection to seizures. Ac-
cording to the medical records these injuries obtained
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no medical attention. Further research is needed to
explore the nature and severity of injuries in connec-
tion with seizures as well as by what means and what
medical attention is received.
Summarising the effects and side effects of treat-
ments given, our study indicates that these are less op-
timal that in most other studies. One reason can be that
adolescents have a poorer compliance than other age
groups1. Another reason for less optimal treatment can
be that the health-care system is unsatisfactory. Ado-
lescents are rarely seen as a group but are considered
as either children or adults. This can cause difficulties
clinically as well as in research, in revealing special
needs and problems related to adolescence. In recent
years there has been a growing interest in develop-
ing special teenage clinics in order to meet the needs
of adolescents with chronic disorders like epilepsy. A
third reason for less optimal treatment can be that ado-
lescent epilepsy per se is more difficult to control than
epilepsy in other age groups. Further, one implication
of our study is that the advances in epilepsy treatment
made in the last decade, do not appear as a better out-
come for this patient group, compared to studies from
the early 1990s. If this finding is valid for other age
groups, it needs be further addressed.
CONCLUSIONS
Many adolescents with uncomplicated epilepsy had
persistent seizures despite treatment at an epilepsy
centre. This in addition to a high reported rate of side
effects of AED treatment, would suggest that treat-
ment is not optimal for this group of patients studied.
As traditional AEDs strongly dominated treatment,
one suggestion is that newly marketed AEDs are un-
derused in this group.
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